Effects of SGLT2 inhibitors on post-operative atrial fibrillation in heart surgery
Official title: Impact of Sodium-glucose Cotransporter 2 Inhibitors on Post-operative Atrial Fibrillation in Cardiothoracic Surgery
Run by Hamad Medical Corporation · NCT06251453 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is trying to see if taking SGLT2 inhibitors before heart surgery can help reduce the chances of developing post-operative atrial fibrillation in patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 3280 (estimated) |
| Sponsor | Hamad Medical Corporation Industry-sponsored |
| Locations | 2 sites (Doha, DA and 1 other locations) |
| Trial ID | NCT06251453 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years old who are undergoing cardiothoracic surgery and have been using SGLT2 inhibitors for at least one week prior to their procedure.
✕Probably not a fit
Patients with known atrial fibrillation on anticoagulation or those with chronic kidney disease and a creatinine clearance of less than 25 mL/min may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the occurrence of post-operative atrial fibrillation (POAF) in patients undergoing various cardiothoracic surgeries, such as coronary artery bypass grafting and valve replacements. It will analyze data from electronic medical records over a six-year period, focusing on the incidence and characteristics of POAF in patients who have used SGLT2 inhibitors for at least one week prior to surgery. The study aims to identify both effectiveness and safety outcomes related to the use of these medications in the surgical context.
Why it matters
Potential benefit: If successful, this study could provide insights into the protective effects of SGLT2 inhibitors against post-operative atrial fibrillation, potentially improving patient outcomes after heart surgery.
How similar studies have gone: While there is emerging evidence suggesting the benefits of SGLT2 inhibitors in reducing atrial fibrillation, this specific approach in the context of post-operative outcomes is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults \> 18 years undergoing cardiothoracic surgery, including CABG, mechanical valve replacement, bioprosthetic valve replacement, or valve repair. * Use of SGLT2 inhibitors for a minimum of 1 week prior to surgery regardless of DM status. * Resumption of SGLT2 inhibitor after stepping down from the intensive care unit. Exclusion Criteria: * Known AF on anticoagulation. * Chronic kidney disease with CrCl \< 25 mL/min.
Where it's running
-
Alaa Rahal
Doha, Da, Qatar Recruiting -
Hamad medical corporation
Doha, Da, Qatar Recruiting
Study contacts
- Study coordinator: Alaa Rahhal, Msc
- Email: ARahhal1@hamad.qa
- Phone: 55712353
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation
This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.
-
Identifying AF patients who may need more than standard ablation using Volta AF-Xplorer II
This trial tests whether AI-identified dispersion areas during AF ablation can predict recurrence after a standard pulmonary vein isolation in patients with persistent AF.
-
4D intracardiac echocardiography to guide left atrial appendage occlusion procedures
A new 4D ICE catheter is being tested alongside standard imaging to see if it can safely guide left atrial appendage occlusion procedures for adults with atrial fibrillation.
-
Thoracoscopic vs Catheter Ablation as the First Rhythm Control in Atrial Fibrillation with a Large Left Atrium
This trial tests whether thoracoscopic surgical ablation is better at keeping atrial fibrillation under control than catheter ablation in people with persistent AF and a large left atrium who have not had an ablation before.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.